Results 1 to 10 of about 1,885,895 (335)

Bruton tyrosine kinase inhibitors for multiple sclerosis

Nature Reviews Neurology, 2023
Bruton tyrosine kinase inhibitors are an emerging treatment for multiple sclerosis. Krämer et al. consider the evidence that central nervous system-penetrant Bruton tyrosine kinase inhibitors might target both peripheral immune cells and ...
Julia Krämer, A. Bar-Or, T. Turner, H. Wiendl   +3 more
semanticscholar   +1 more source

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

New England Journal of Medicine, 2022
BACKGROUND Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL).
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya, R. Notti, J. Afaghani, B. Durham, A. Penson, Matthew T. Witkowski, Sydney X. Lu, J. Bourcier, S. Hogg, C. Erickson, Daniel Cui, Hana Cho, Michael Singer, T. Totiger, S. Chaudhry, M. Geyer, Alvaro J. Alencar, A. Linley, M. Palomba, Catherine C. Coombs, Jae H. Park, A. Zelenetz, L. Roeker, M. Rosendahl, Donald E. Tsai, K. Ebata, B. Brandhuber, D. Hyman, I. Aifantis, A. Mato, Justin Taylor, O. Abdel-Wahab   +34 more
semanticscholar   +1 more source

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors

Current Cardiology Reports, 2023
Purpose of Review To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types.
N. Sayegh, J. Yirerong, N. Agarwal, D. Addison, M. Fradley, Jorge Cortes, Neal L Weintraub, Nazish Sayed, G. Raval, A. Guha   +9 more
semanticscholar   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

npj Breast Cancer, 2021
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib ...
I. Schlam, S. Swain
semanticscholar   +1 more source

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Molecules, 2022
Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma (NSCLC) is still quite low in the majority of cases.
T. Amelia, R. E. Kartasasmita, T. Ohwada, D. H. Tjahjono   +3 more
semanticscholar   +1 more source

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Cancers, 2021
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine kinase oncoprotein BCR-ABL1.
R. Alves, A. Gonçalves, S. Rutella, A. Almeida, J De Las Rivas, I. Trougakos, A. B. Sarmento Ribeiro   +6 more
semanticscholar   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source